CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $6.91M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 7.45: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.61BCNY537.15M · vs all stocks (USD)
Revenue (TTM)
46.50MCNY6.91M · vs all stocks (USD)
Profit Margin
-290.42%vs Biotechnology peers
Beta
-0.0670xvs all stocks
52-Week Change
-40.99%vs all stocks
Market Capitalization
3.61BCNY537.15M · vs all stocks (USD)
Enterprise Value
2.79BCNY415.40M · vs all stocks (USD)
Price to Sales (TTM)
75.62xvs Biotechnology peers
Price to Book (MRQ)
3.40xvs Biotechnology peers
Enterprise to Revenue
60.08xvs Biotechnology peers
Enterprise to EBITDA
-17.28xvs Biotechnology peers
Gross Margin
99.82%vs Biotechnology peers
Profit Margin
-290.42%vs Biotechnology peers
Operating Margin
-117.48%vs Biotechnology peers
Return on Assets (TTM)
-8.01%vs Biotechnology peers
Return on Equity (TTM)
-12.29%vs Biotechnology peers
Revenue (TTM)
46.50MCNY6.91M · vs all stocks (USD)
Revenue per Share (TTM)
0.4720CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-1003.06%vs Biotechnology peers
Gross Profit (TTM)
46.17MCNY6.87M · vs all stocks (USD)
EBITDA (TTM)
-161.69MCNY-24.04M · vs all stocks (USD)
Net Income (TTM)
-135.03MCNY-20.08M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
10022.67%vs Biotechnology peers
Operating Cash Flow (TTM)
-84.75MCNY-12.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-53.46MCNY-7.95M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
20.47MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
282.82KCNYFY2025 · Dec 31, 2025Gross Profit
20.19MCNYFY2025 · Dec 31, 2025Operating Income
-157.36MCNY-23.40M · vs all stocks (USD)
Pre-tax Income
-137.25MCNYFY2025 · Dec 31, 2025Income Tax Expense
3.04KCNYFY2025 · Dec 31, 2025Net Income
-137.25MCNYFY2025 · Dec 31, 2025EBIT
-136.90MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-139.07MCNYFY2025 · Dec 31, 2025Research & Development
112.71MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
39.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
901.65KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.39MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
354.11KCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.39CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.39CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
98.74MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
98.74MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-137.25MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-139.20MCNYFY2025 · Dec 31, 2025Free Cash Flow
-222.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
437.59MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-137.25MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-451.50KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.35MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.84MCNYFY2025 · Dec 31, 2025Capital Expenditures
-82.89MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.59BCNYFY2025 · Dec 31, 2025Sale of Investments
2.49BCNYFY2025 · Dec 31, 2025Other Investing Activity
34.74MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-139.70MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
100.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.24MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.52MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
95.24MCNYFY2025 · Dec 31, 2025Shares Outstanding
99.02MSharesUpdated Aug 21, 2026Float Shares
71.83MSharesUpdated Aug 21, 2026% Held by Insiders
29.31%vs all stocks
% Held by Institutions
9.22%vs all stocks
Total Cash (MRQ)
827.74MCNY123.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.36CNYUpdated Aug 21, 2026Total Debt (MRQ)
105.04MCNY15.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1016xvs Biotechnology peers
Current Ratio (MRQ)
7.04xvs Biotechnology peers
Book Value per Share (MRQ)
10.44CNYUpdated Aug 21, 2026Total Assets
1.31BCNY194.77M · vs all stocks (USD)
Total Current Assets
906.34MCNYFY2025 · Dec 31, 2025Total Liabilities
246.19MCNYFY2025 · Dec 31, 2025Total Non-current Assets
403.41MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
120.28MCNYFY2025 · Dec 31, 2025Total Current Liabilities
125.90MCNYFY2025 · Dec 31, 2025Cash
436.88MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
438.18MCNYFY2025 · Dec 31, 2025Other Short-term Investments
310.59MCNYFY2025 · Dec 31, 2025Accounts Receivable
2.70KCNYFY2025 · Dec 31, 2025Inventory
2.85MCNYFY2025 · Dec 31, 2025Accounts Payable
88.55MCNYFY2025 · Dec 31, 2025Short-term Debt
3.30MCNYFY2025 · Dec 31, 2025Other Current Liabilities
521.50KCNYFY2025 · Dec 31, 2025Long-term Debt
102.59MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
203.96KCNYFY2025 · Dec 31, 2025Common Stock (Book)
99.02MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.63BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.06BCNY158.16M · vs all stocks (USD)
52-Week Low
31.90CNYUpdated Aug 21, 202652-Week High
63.98CNYUpdated Aug 21, 202652-Week Change
-40.99%vs all stocks
Beta
-0.0670xvs all stocks
50-Day MA
36.12CNYUpdated Aug 21, 2026200-Day MA
43.29CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.90MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.96MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.37CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -2.90
Financial Health
Altman Z-Score 7.45: safe zoneNotable
Altman Z-Score: 7.45
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $6.91M, lower than 95% of all stocks globallySignificant
Revenue (USD): 6,914,324.391Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Posiflex Technology Inc.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Top Bright Holding Co. Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Acimmune SA
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC